Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

Abstract : Purpose: The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods: Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 μg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Adverse events (AEs), including predefined dose-limiting toxicity (DLT) and the anti-PRAME humoral response (ELISA), were coprimary end points. Cellular immune responses were evaluated using in vitro assays. Results: 66 patients were treated (20, 24 and 22 in the respective cohorts). AEs considered by the investigator to be causally related were mostly grade 1 or 2 injection site symptoms, fatigue, chills, fever and headache. Two DLTs (grade 3 brain oedema and proteinuria) were recorded in two patients in two cohorts (cohorts 2 and 3). All patients had detectable anti-PRAME antibodies after four immunisations. Percentages of patients with predefined PRAME-specific-CD4+T-cell responses after four immunisations were similar in each cohort. No CD8+ T-cell responses were detected. Conclusions: The PRAME immunotherapeutic had an acceptable safety profile and induced similar anti-PRAME-specific humoral and cellular immune responses in all cohorts. As per protocol, the phase II study segment was initiated to further evaluate the 500 μg PRAME immunotherapeutic dose.
Type de document :
Article dans une revue
ESMO Open, BMJ Journals, 2016, 1 (4), pp.e000068. 〈10.1136/esmoopen-2016-000068〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01406639
Contributeur : Elizabeth Bernardo <>
Soumis le : jeudi 1 décembre 2016 - 14:01:29
Dernière modification le : jeudi 18 janvier 2018 - 02:26:09

Lien texte intégral

Identifiants

Collections

Citation

R. Gutzmer, Licia Rivoltini, E. Levchenko, A. Testori, J. Utikal, et al.. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open, BMJ Journals, 2016, 1 (4), pp.e000068. 〈10.1136/esmoopen-2016-000068〉. 〈inserm-01406639〉

Partager

Métriques

Consultations de la notice

49